-
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid TumorsDaiichi Sankyo2026-06-30 16:06:21Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for
-
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for ImmunotherapyDaiichi Sankyo2026-06-30 16:03:43Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic
-
Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026Daiichi Sankyo2026-06-09 16:24:17Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS
-
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid TumorsDaiichi Sankyo2026-06-09 12:59:47Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive
-
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&DDaiichi Sankyo2026-02-20 09:50:18Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
-
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast CancerDaiichi Sankyo2026-02-19 09:46:13ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with
-
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center EuropeDaiichi Sankyo2026-01-22 08:47:57Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
-
ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2026-01-19 10:21:05ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients
-
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern EuropeDaiichi Sankyo2026-01-08 18:23:36Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and
-
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for ImmunotherapyDaiichi Sankyo2026-01-08 18:09:17DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with
